Coronavirus SARS-CoV-2 infection: multiple sclerosis (MS) recommendations

Evidence-based neurology checklist on coronavirus sars-cov-2 infection: multiple sclerosis (ms) recommendations: DMTs with very low infection risk Interferon beta 1a Interferon beta 1b Glatiramer acetate Teriflunomide Dimethyl fumarate DMTs with low infection risk DMTs with moderate infection risk…

DMTs with very low infection risk

  • Interferon beta 1a
  • Interferon beta 1b
  • Glatiramer acetate
  • Teriflunomide
  • Dimethyl fumarate

DMTs with low infection risk

DMTs with moderate infection risk

DMTs with high infection risk

Recommendations if not infected

Recommendations if infected

Synonym

References

  1. Coles A, Lim M, Giovannoni G, Anderson P. ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. ABN 2020. Sourced 03.04.20.
  2. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Rel Disord 2020 (Epub ahead of print).
  3. Association of British Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and carers. ABN 2020. Accessed 02.04.2020.
  4. von Oertzen TJ, Macerollo A, Leone MA, et al. EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. Eur J Neurol 2021; 28:7-14. 

Related checklists

Loading...